Analysts Set $39.01 Price Target for Inflarx NV (IFRX)
Shares of Inflarx NV (NASDAQ:IFRX) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus price target of $39.01 for the company and are forecasting that the company will post ($0.34) EPS for the current quarter, according to Zacks. Zacks has also assigned Inflarx an industry rank of 114 out of 265 based on the ratings given to related companies.
IFRX has been the topic of a number of research reports. Zacks Investment Research downgraded shares of Inflarx from a “hold” rating to a “sell” rating in a research report on Saturday, April 7th. Leerink Swann boosted their target price on shares of Inflarx from $31.00 to $36.00 and gave the company an “outperform” rating in a research report on Monday, April 2nd. Finally, B. Riley initiated coverage on shares of Inflarx in a research report on Thursday, February 8th. They set a “buy” rating and a $40.00 target price on the stock.
Shares of Inflarx stock traded down $0.01 during trading on Friday, reaching $38.08. 3,819 shares of the company traded hands, compared to its average volume of 59,463. Inflarx has a 1-year low of $14.47 and a 1-year high of $40.17.
TRADEMARK VIOLATION WARNING: “Analysts Set $39.01 Price Target for Inflarx NV (IFRX)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2018/04/25/analysts-set-39-01-price-target-for-inflarx-nv-ifrx.html.
Inflarx Company Profile
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.